Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL27153440 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL94550 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL209483 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL30286660 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL16893958 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| D-Histidine SCHEMBL8002457 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL139654 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3985696 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL16893957 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3985692 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114748618-B | Pharmaceutical formulation comprising bispecific antibodies against rabies virus G protein and method for preparing same | 重庆智翔金泰生物制药股份有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-117919210-A | Inhalable compositions of anti-RBD antibodies or antigen-binding fragments thereof | 盛禾(中国)生物制药有限公司 | 2024-04-26 | — | — | CN | claimed |
| WO-2024086013-A1 | USTEKINUMAB DOSAGE FORMS AND METHODS | RANI THERAPEUTICS, LLC (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2024081329-A1 | MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF | MARENGO THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| WO-2024078521-A1 | FORMULATION INCLUDING ANTI-VEGFR2 ANTIBODY | 苏州创胜医药集团有限公司 | 2024-04-18 | — | — | WO | claimed |
| EP-4337253-A2 | PHARMACOKINETIC & PHARMACODYNAMIC MODEL FOR DETERMINING EFFECTIVE DOSE OF ANTI-TICAGRELOR ANTIBODY | Sfj Pharmaceuticals X, Ltd. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2024042250-A1 | PHARMACEUTICAL FORMULATION AND DOSING REGIMEN FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | AL-S PHARMA AG (CH) | 2024-02-29 | — | — | WO | claimed |
| US-11912764-B2 | Anti-connexin antibody formulations | ALAMAB THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | claimed |
| CN-117427157-A | Stable preparation of fully human anti-PD-1 monoclonal antibody | 广州誉衡生物科技有限公司 | 2024-01-23 | — | — | CN | claimed |
| US-20230414760-A1 | PHARMACEUTICAL FORMULATION | ASTRAZENECA UK LIMITED (GB) | 2023-12-28 | — | — | US | claimed |
| EP-3337502-A1 | STABLE ANTI-IFNAR1 FORMULATION | Astrazeneca AB (SE) | 2018-06-27 | — | — | EP | claimed |
| US-20170281769-A1 | STABLE ANTI-IL-4Ra FORMULATION | MEDIMMUNE LIMITED (GB) | 2017-10-05 | — | — | US | claimed |
| WO-2017129685-A1 | LIQUID FORMULATION OF A VEGF ANTAGONIST | FORMYCON AG (DE) | 2017-08-03 | — | — | WO | claimed |
| EP-3188757-A1 | STABLE ANTI-IL-4R-ALPHA ANTIBODY FORMULATION | Medimmune Limited (GB) | 2017-07-12 | — | — | EP | claimed |
| WO-2017031288-A1 | STABLE ANTI-IFNAR1 FORMULATION | MEDIMMUNE, LLC (US) | 2017-02-23 | — | — | WO | claimed |
| US-20170051066-A1 | STABLE ANTI-IFNAR1 FORMULATION | MEDIMMUNE, LLC (US) | 2017-02-23 | — | — | US | claimed |
| US-20160297877-A1 | Pharmaceutical composition of an anti-VEGF antibody | FORMYCON AG (DE) | 2016-10-13 | — | — | US | claimed |
| EP-3071181-A1 | PHARMACEUTICAL COMPOSITION OF AN ANTI-VEGF ANTIBODY | Formycon AG (DE) | 2016-09-28 | — | — | EP | claimed |
| WO-2016034648-A1 | STABLE ANTI-IL-4R-ALPHA ANTIBODY FORMULATION | MEDIMMUNE LIMITED (GB) | 2016-03-10 | — | — | WO | claimed |
| WO-2015071348-A1 | PHARMACEUTICAL COMPOSITION OF AN ANTI-VEGF ANTIBODY | FORMYCON AG (DE) | 2015-05-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170051066-A1 | STABLE ANTI-IFNAR1 FORMULATION | IFNAR1, IRF3, IFNG | PTGS1 1499/4885SLC7A5 2769/4885CYP3A4 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.